Fusion Pharmaceuticals Inc. (USD) Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines. The company has developed Targeted Alpha Therapies platform together with its proprietary Fast-Clear linker technology to enable us to connect alpha particle emitting isotopes to various targeting molecules in order to selectively deliver the alpha particle payloads to tumors. Its lead product candidate is FPI-1434 that is in Phase 1 clinical trials as a monotherapy in patients with solid tumors expressing insulin-like growth factor 1 receptor. The company is also conducting additional preclinical studies of FPI-1434 in combination with approved checkpoint inhibitors and DNA damage response inhibitors to further assess the anti-tumor activity, and dosing schedule and pharmacodynamics of the combinations. In addition, it is progressing its earlier-stage product candidate, FPI-1966 into clinical development for the treatment of head and neck, and bladder cancers expressing fibroblast growth factor receptor. The company has a strategic collaboration agreement with AstraZeneca UK Limited to jointly discover, develop, and commercialize alpha-emitting radiopharmaceuticals and combination therapies for the treatment of cancer. Fusion Pharmaceuticals Inc. was incorporated in 2014 and is headquartered in Hamilton, Canada.

Fusion Pharmaceuticals Inc. (USD) Passive

270 Longwood Road South, Hamilton, ON, CA, L8P 0A6

Stock Price USD

Price Change

Last Dividend USD

FUSN's stock peer is BCAB (BioAtla, Inc.)

FUSN's stock peer is BCYC (Bicycle Therapeutics plc)

FUSN's stock peer is BOLT (Bolt Biotherapeutics, Inc.)

FUSN's stock peer is CHRS (Coherus BioSciences, Inc.)

FUSN's stock peer is EWTX (Edgewise Therapeutics, Inc.)

FUSN's stock peer is FENC (Fennec Pharmaceuticals Inc.)

FUSN's stock peer is GRCL (Gracell Biotechnologies Inc.)

FUSN's stock peer is HRMY (Harmony Biosciences Holdings, Inc.)

FUSN's stock peer is IKNA (Ikena Oncology, Inc.)

FUSN's stock peer is JANX (Janux Therapeutics, Inc.)

FUSN's stock peer is KROS (Keros Therapeutics, Inc.)

FUSN's stock peer is NAMS (NewAmsterdam Pharma Company N.V.)

FUSN's stock peer is NLTX (Neoleukin Therapeutics, Inc.)

FUSN's stock peer is OLMA (Olema Pharmaceuticals, Inc.)

FUSN's stock peer is PASG (Passage Bio, Inc.)

FUSN's stock peer is PMVP (PMV Pharmaceuticals, Inc.)

FUSN's stock peer is RAPT (RAPT Therapeutics, Inc.)

FUSN's stock peer is RLMD (Relmada Therapeutics, Inc.)

FUSN's stock peer is SPRO (Spero Therapeutics, Inc.)

Healthcare Biotechnology

Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines. The company has developed Targeted Alpha Therapies platform together with its proprietary Fast-Clear linker technology to enable us to connect alpha particle emitting isotopes to various targeting molecules in order to selectively deliver the alpha particle payloads to tumors. Its lead product candidate is FPI-1434 that is in Phase 1 clinical trials as a monotherapy in patients with solid tumors expressing insulin-like growth factor 1 receptor. The company is also conducting additional preclinical studies of FPI-1434 in combination with approved checkpoint inhibitors and DNA damage response inhibitors to further assess the anti-tumor activity, and dosing schedule and pharmacodynamics of the combinations. In addition, it is progressing its earlier-stage product candidate, FPI-1966 into clinical development for the treatment of head and neck, and bladder cancers expressing fibroblast growth factor receptor. The company has a strategic collaboration agreement with AstraZeneca UK Limited to jointly discover, develop, and commercialize alpha-emitting radiopharmaceuticals and combination therapies for the treatment of cancer. Fusion Pharmaceuticals Inc. was incorporated in 2014 and is headquartered in Hamilton, Canada.

Income Statement

Dividend Stats Yield is calculated via trailing-12-month period

Ex-Dividend	Payment Date	Dividend	Yield	Dividend Frequency
Dividend Data Not Exist

Disclaimers

StockQuay.com is not operated by a broker, dealer, or registered investment advisor. Under no circumstances should any information published on StockQuay.com be considered a recommendation to buy, sell, or hold any security. The content on this site and in its associated newsletters is intended solely for informational and educational purposes and does not constitute investment advice or financial recommendations.

Individuals or entities featured or referenced on StockQuay.com may engage in trading activity involving the securities mentioned in any article or report before or after such content is published. These individuals or entities are not affiliated with StockQuay.com, and their inclusion does not imply endorsement or accuracy of their views or actions.

StockQuay.com, its owners, or its affiliates shall not be held liable to any user or third party for any damages or losses arising from the use of content on this website. This includes, but is not limited to, investment losses, loss of profit, loss of data, missed opportunities, or indirect, incidental, or consequential damages.

Data is updated daily and is not guaranteed to be accurate or complete.

Past performance is not indicative of future results. Please conduct your own research or consult with a qualified financial advisor before making any investment decisions